



The Native Antigen Company Introduces Range of Veterinary Reagents

Antigens and antibodies for livestock and companion animal diseases to support development of diagnostics and vaccines

Oxford, UK, 20 January 2021: The Native Antigen Company (now part of LGC Clinical Diagnostics), one of the world's leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of its new range of veterinary reagents. The Company's offering includes over 90 high-quality native and recombinant antigens, and monoclonal and polyclonal antibodies for a range of viral, bacterial and protozoal veterinary diseases, that can be used in the development of diagnostics and vaccines.

The Company's reagents have been developed for both livestock and companion animals, such as dogs, cats and pigs, and include a range of clinically relevant pathogens, such as coronaviruses, *Borrelia*, Rift Valley fever virus, African swine fever virus, *Toxocara* and heartworm. Suitable for a wide range of applications, these reagents can be used in research, as well as the development of immunoassays for diagnostic and vaccine R&D. The Company is continuing to expand its veterinary range and is well-positioned to respond to emerging health threats.

Dr Andy Lane, Commercial Director, The Native Antigen Company, said: *"With a growing appreciation of One Health and the relationship between zoonotic human and animal diseases, The Native Antigen Company aims to support the development of much-needed diagnostics and vaccines to endemic and emerging veterinary pathogens. This marks the Company's first move into the veterinary reagent market, which we expect to grow rapidly over the coming years."*

For further information about The Native Antigen Company's veterinary reagents, please visit: <https://thenativeantigencompany.com/veterinary-reagents/>

ENDS

Notes to Editors



Dr Andy Lane, Commercial Director at The Native Antigen Company



Photograph of Toxocara parasite known to infect dogs.

For high-resolution images please contact Zyme Communications.

For further information please contact:

The Native Antigen Company
James Shore
Tel: +44 (0) 1865 595 230
Email: james.shore@LGCGroup.com

Zyme Communications
Dr Michelle Ricketts
Tel: +44 (0)7789 053885
Email: michelle.ricketts@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please [click here](#).

About The Native Antigen Company thenativeantigencompany.com

The Native Antigen Company is one of the world's leading suppliers of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases. The Native Antigen Company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, alongside bespoke product development and custom manufacturing using its proprietary mammalian cell expression system.

The Native Antigen Company's team have decades of experience in the isolation and purification of native antigens and high-yield mammalian cell expression systems, ensuring conformity to native type. The Company's high-quality reagents have been widely adopted by leading pharmaceutical, *in vitro* diagnostic assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.

The Native Antigen Company prides itself on an ethical and sustainable approach, exemplified by its use of 100% renewable energy and recycled packaging wherever possible, and building honest and transparent relationships with its customers and collaborators.

Founded in 2010, The Native Antigen Company is located in Oxford (UK) and has a global network of distributors.

Follow The Native Antigen Company on Twitter [@nativeantigen](https://twitter.com/nativeantigen) and LinkedIn [@The Native Antigen Company](https://www.linkedin.com/company/the-native-antigen-company/)

About LGC Clinical Diagnostics <https://www.lgcgroup.com/who-we-serve/healthcare/clinical-diagnostics/>

LGC's Clinical Diagnostics Division develops and manufactures a comprehensive portfolio of catalogue and custom-developed diagnostic quality solutions and component materials for the extended life sciences industry. We partner with IVD assay developers, and pharmaceutical, CRO and academic institutions in commercialization activities across the entire diagnostic pipeline - from concept and early stage research, through expedited product development and onwards into routine clinical use. Laboratorians and diagnostic professionals across disciplines of clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics rely on LGC's products to support accurate and reliable diagnostic results.

Our operating entities include [SeraCare Life Sciences](#) and [Maine Standards Company](#), which are *in vitro* diagnostics (IVD) manufacturers of quality measurement tools (calibrators, controls, linearity, EQA/PT, biological materials) and The Native Antigen Company, which is a manufacturer and supplier of viral antigens. Our 300+ employees operate FDA-registered and ISO 13485-accredited

facilities in Maine, Massachusetts and Maryland, USA, and an ISO 9001-accredited facility in Oxford, UK.

Each day, our world-class staff, scientific expertise, operational efficiency and superior quality systems are ready to support the range of advanced technologies that collectively improve patient outcomes - from the widely adopted and established through to cutting-edge NGS and precision diagnostics.